EZH2 and diffuse large B-cell lymphoma: Further evaluation of EZH2 inhibition in combination with PD-L1 blockade may be warranted in patients with DLBCL or FL, ideally including patients with both activating and inactivating mutations, given that the EZH2 mutation-specific efficacy of tazemetostat is unclear.